Egetis Therapeutics News and Activities

Egetis Therapeutics is a company listed under the stock ticker EGTX (SE).

View the org chart displaying its 23 main executives

Most searched biographies at Egetis Therapeutics

• Nicklas Westerholm, Chief Executive Officer
• Margarida Duart, Director
• Elisabeth Svanberg, Board Member

Popular executive movements at Egetis Therapeutics

• Kristina Nygren, who is Chief Medical Officer will soon leave the company  (posted on April 9 2026).
• Tiago Nunes will join the company as Chief Medical Officer on May 1, 2026  (posted on April 9 2026).
• Desiree Luthman, Vice President, Global Regulatory Affairs, has left the company  (posted on April 9 2026).

Create your alert
to follow the executive moves at Egetis Therapeutics.

Egetis Therapeutics has 2,406 competitors including Eurofins (Luxembourg), Lonza (Switzerland) and BioNTech (Germany).

Popular M&A news in Biotechnology

• Oak Hill Bio has just announced a $33 Million fundraising (posted on June 4 2026).
• IMU Biosciences has just announced a $53 Million fundraising (posted on June 3 2026).
• NewLimit has just announced a $435 Million fundraising (posted on June 3 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Valerie Hanote - Non-Executive Director at Eurofins

Learn more about the Biotechnology industry

Press releases by Egetis Therapeutics

• Change in the number of shares and votes in Egetis Therapeutics - Egetis Therapeutics
• Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026 - Egetis Therapeutics
• Exercise of options under employee stock option program and notification of insider trading - Egetis Therapeutics
• Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 - Egetis Therapeutics
• Egetis Announces Grant of Patent for MCT8 Deficiency Composition in the U.S. - Egetis Therapeutics
• Interim report Q1 2026 - Egetis Therapeutics
• Egetis Therapeutics to Participate in Pediatric Endocrine Society Annual Meeting 2026 - Egetis Therapeutics
• Change in the number of shares and votes in Egetis Therapeutics - Egetis Therapeutics
• Egetis Therapeutics announces the intention to carry out a directed share issue of approximately SEK 350 million (approximately USD 38 million) - Egetis Therapeutics
• Invitation to Presentation of Egetis’ First Quarter 2026 Report on April 29, 2026 - Egetis Therapeutics
• View more press releases Close

Social media about Egetis Therapeutics

• Egetis Therapeutics on Wikipedia, Google News & Yahoo Finance
• Egetis Therapeutics on LinkedIn, X (Twitter) & YouTube